Bevacizumab for front-Line Treatment of Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer Patients With High Risk of Relapse- a Cost Effective option for Canadian Patients
Abstract
Authors
P. Ghatage E.J. Wright I. Martin Nunez L. Yin J. Ray